Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Ovarian Cancer (Brca1, Brca2, Homologous Recombination Deficiency, Ntrk) (Retired 7/1/2026)

Capital Blue Cross · PayerPolicy · CAPBLUE-MP-2.395

Source checked October 1, 2026 · Open the payer’s source

Status: Retired

Summary of the payer’s published policy. Not a coverage determination — confirm with Capital Blue Cross before submitting.

This version is retired

Capital Blue Cross has replaced or withdrawn this version, and Backwork could not match it to a current one. The payer’s current policies are listed on its page.

Capital Blue Cross policies Payer’s source